Biomedical applications of protein chips

Ng, Jocelyn H.; Ilag, Leodevico L.

doi:10.1111/j.1582-4934.2002.tb00512.x

Cited by 26 publications

(12 citation statements)

References 94 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Innovative antibody-based methods to improve protein measurements, such as stable isotope standards and capture by anti-peptide antibodies (SISCAPA), are already being applied in mass spectrometry platforms to quantify peptides in complex mixtures (21). Additionally the combination of microarray technology and proteomics reagents has led to the development of "proteome chips," which offer the potential for the multiplexed analysis of hundreds to thousands of proteins in parallel (22,23). These chips represent a promising application for large scale, cost-effective screening for numerous proteomics applications, including identifying protein-drug and protein-lipid interactions and post-translational modifications (24).…”

Section: Affinity Capture Reagents In Discovery and Translational Resmentioning

confidence: 99%

A Reagent Resource to Identify Proteins and Peptides of Interest for the Cancer Community

Haab

Paulovich

Anderson³

et al. 2006

Molecular & Cellular Proteomics

View full text Add to dashboard Cite

On the basis of discussions with representatives from all sectors of the cancer research community, the National Cancer Institute (NCI) recognizes the immense opportunities to apply proteomics technologies to further cancer research. Validated and well characterized affinity capture reagents (e.g. antibodies, aptamers, and affibodies) will play a key role in proteomics research platforms for the prevention, early detection, treatment, and monitoring of cancer. To discuss ways to develop new resources and optimize current opportunities in this area, the NCI convened the "Proteomic Technologies Reagents Resource Workshop" in Chicago, IL on December 12-13, 2005. The workshop brought together leading scientists in proteomics research to discuss model systems for evaluating and delivering resources for reagents to support MS and affinity capture platforms. Speakers discussed issues and identified action items related to an overall vision for and proposed models for a shared proteomics reagents resource, applications of affinity capture methods in cancer research, quality control and validation of affinity capture reagents, considerations for target selection, and construction of a reagents database. The meeting also featured presentations and discussion from leading private sector investigators on state-of-the-art technologies and capabilities to meet the user community's needs. This workshop was developed as a component of the NCI's Clinical Proteomics Technologies Initiative for Cancer, a coordinated initiative that includes the establishment of reagent resources for the scientific community. This workshop report explores various approaches to develop a framework that will most effectively fulfill the needs of the NCI and the cancer research community. Molecular

show abstract

Section: Affinity Capture Reagents In Discovery and Translational Resmentioning

confidence: 99%

A Reagent Resource to Identify Proteins and Peptides of Interest for the Cancer Community

Haab

Paulovich

Anderson³

et al. 2006

Molecular & Cellular Proteomics

View full text Add to dashboard Cite

show abstract

“…For example, the studies described in Subheading 4.2.1. relating the expression ofNHEJ factors to radiosensitivity were potentially compromised by our incomplete knowledge of the genes/proteins involved in that pathway (314), such that limiting screening to known repair factors might not always give correlations with radiosensitivity. However, the advent of cDNA microarrays (315,316) and, more recently, protein chip technologies (317)(318)(319) has enabled the rapid screening of thousands of genes and proteins without the prerequisite for knowledge of their activity. The expression profile of genes believed to be involved in radiosensitivity has recently been characterized by microarrays in cervical cancer cell lines (320) and inhead and neck cancer (321).…”

Section: Discussionmentioning

confidence: 99%

DNA Repair in Cancer Therapy

Panasci¹,

Alaoui‐Jamali²

2004

View full text Add to dashboard Cite

All rights reserved. No part of this book may be reproduced, stored in a retrieval system. Of transmitted in any form or by any means, electronic, mechanical. photocopying. microfilming, recording, or otherwise without written permission from the Publisher.The content and opinions expressed in this book arc the sole v..'ork of the authors and editors. who have warranted due diligence in the creation and issuance of their work. The publisher, editors, and authors are not responsible for errors or omissions or for any consequence arising from the information or opinions presented in this book and make no warranty. express or implied, with respect to its contents.Due diligence has been taken by the publishers. editors. and authors of this book to assure the accuracy of the information published and to describe generally accepted practices. The contributors herein have carefully checked to ensure that the drug selections and dosages set forth in this text are accurate and in accord with the standards accepted at the time of publication. Notwithstanding, as new research. changes in government regulations. and knowledge from clinical experience relating to drug therapy and drug reactions constantly occurs. the reader is advised to check the product information provided by the manufacturer of each drug for any change in dosages or for additional warnings and contraindications. This is of utmost importance when the recommended drug herein is a new or infrequently used drug. It is the responsibility of the treating physician to determine dosages and treatment strategies for individual patients. Further it is the responsibility of the health care provider to ascertain the Food and Drug Administration status of each drug or device used in their clinical practice. The Library of Congress Cataloging-in-Publication Data DNA repair in cancer therapy / edited by Lawrence C. Pan asci and Moulay A. Alaoui-lamali p. ; cm. --(Cancer drug discovery and development) Includes bibliographical references and index ISBN 978-1-61737-480-7 ISBN 978-1-59259-735-2 (eBook)

show abstract

“…The design of diagnostic protein chips has focused on clinical applications (23,24 ). Ekins and Chu (25 ) suggested that quantitative immunoassays could be developed that use microspots of antibodies on nonporous solid supports, thereby enabling multianalyte assays, but it was only recently that such testing biochips have become a reality (26 -29 ).…”

Section: Discussionmentioning

confidence: 99%

Development of Miniaturized Competitive Immunoassays on a Protein Chip as a Screening Tool for Drugs

Yang

et al. 2005

Clinical Chemistry

View full text Add to dashboard Cite

Background: Doping in sports has become a serious problem. Gas chromatography-mass spectrometry (GC-MS) serves as an effective reference method, but it is limited by low throughput and is therefore not suitable for large-scale screening. Use of protein chips for highthroughput screening of all athletes for prohibited substances could become an important complementary tool to GC-MS. Methods: We developed a protein chip based on an aldehyde-activated glass slide containing 10 physically isolated arrays. The chip was used to screen urine from 1347 athletes for prohibited substances and to screen a negative control group consisting of 200 females and 120 males. Urine samples from 66 individuals known to be abusers, provided by the China Doping Control Center (CDCC), and 129 standard prohibited substances were tested as positive controls. Results: All 1347 urine samples screened by means of the protein chips were also subjected to reference analysis by GC-MS at the CDCC. There was no qualitative difference between the results obtained with the two methods. The correlation coefficient (r 2 ) for the quantitative results obtained with the protein chip and GC-MS was 0.991.

show abstract

Biomedical applications of protein chips

Cited by 26 publications

References 94 publications

A Reagent Resource to Identify Proteins and Peptides of Interest for the Cancer Community

A Reagent Resource to Identify Proteins and Peptides of Interest for the Cancer Community

DNA Repair in Cancer Therapy

Development of Miniaturized Competitive Immunoassays on a Protein Chip as a Screening Tool for Drugs

Contact Info

Product

Resources

About